OGG1 Activator Program
Neurodegenerative Diseases
Pre-clinicalActive
Key Facts
About Luciole Pharmaceuticals
Luciole Pharmaceuticals is pioneering a novel therapeutic approach centered on mitochondrial DNA repair. The company is developing small molecule activators of the OGG1 enzyme, aiming to enhance the base excision repair pathway to correct oxidative damage to mtDNA, thereby addressing mitochondrial dysfunction and the associated inflammatory cascade. Its strategy targets the root cause of several age-related neurodegenerative diseases. The company leverages a virtual model and is led by a team with deep expertise in mitochondrial biology, drug discovery, and development.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| PBI-01207 | Phoenix Biotechnology | Pre-clinical |
| Therapeutic Target Discovery Platform | ValtedSeq | Discovery |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| Platform Application for Neurodegenerative Diseases | ALTUCELL | Pre-clinical/Research |
| Lysosome Biology Program | Talisman Therapeutics | Preclinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegenerative Biomarkers R&D | Firalis | Development |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |